Markets:

Overview

News

Currencies

International

Treasuries

Revolution Medicines, Inc. - Common Stock (NQ:RVMD)

160.65 +2.88 (+1.82%)

Streaming Delayed Price Updated: 12:25 PM EDT, Jun 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revolution Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

August 01, 2023

Gainers Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 01, 2023

Via Benzinga

Revolution Medicines Earnings Preview ↗

May 05, 2023

Via Benzinga

Where Revolution Medicines Stands With Analysts ↗

April 12, 2023

Via Benzinga

Why Revolution Medicines Stock Is Trading Lower ↗

March 02, 2023

Revolution Medicines Inc (NASDAQ: RVMD) shares are trading lower by 8.77% to $24.18 Thursday morning after the company announced a $300 million offering of common stock.

Via Benzinga

Revolution Medicines To Acquire EQRx In All-Stock Transaction To Gain Over $1B In Additional Capital ↗

August 01, 2023

Revolution Medicines Inc (NASDAQ: RVMD) has agreed to acquire EQRx Inc (NASDAQ: EQRX) in an all-stock transaction intended to add more than $1 billion in net cash to

Via Benzinga

RVMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Revolution Medicines, Inc. Is Fair to Shareholders

August 01, 2023

From Halper Sadeh LLC

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 01, 2023

Via Benzinga

Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital

August 01, 2023

From Revolution Medicines, Inc.; EQRx, Inc.

Via GlobeNewswire

Revolution Medicines Earnings Preview ↗

February 24, 2023

Via Benzinga

Where Revolution Medicines Stands With Analysts ↗

December 14, 2022

Via Benzinga

Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names ↗

April 20, 2023

Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...

Via Benzinga

$140M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying ↗

March 13, 2023

Although US stocks closed lower on Friday, there were a few notable insider trades.

Via Benzinga

Why Revolution Medicines Shares Are Trading Higher Today ↗

February 28, 2023

Revolution Medicines, Inc. (NASDAQ: RMVD) shares are trading higher after the company reported better-than-expected fourth-quarter results.

Via Benzinga

Revolution Medicines' Early-Data Validation For Cancer Program Wins Price Target Boost By This Analyst ↗

February 28, 2023

Via Benzinga

Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday ↗

February 28, 2023

U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023 ↗

February 28, 2023

Via Benzinga

Chefs' Warehouse, Chart Industries And Some Other Big Stocks Moving Lower On Thursday ↗

December 08, 2022

U.S. stocks traded higher, with the Dow Jones jumping over 200 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Revolution Medicines Regains Global Rights To Mid-Stage Cancer Program As Sanofi Terminates Collaboration ↗

December 08, 2022

Via Benzinga

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

November 07, 2022

From Revolution Medicines, Inc.

Via GlobeNewswire

Earnings Scheduled For February 27, 2023 ↗

February 27, 2023

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022 ↗

December 14, 2022

Via Benzinga

Earnings Scheduled For November 7, 2022 ↗

November 07, 2022

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

Via Benzinga

LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday ↗

August 12, 2022

WeTrade Group, Inc. (NASDAQ: WETG) jumped 46% to $20.56 after the company announced it entered into a sales agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022 ↗

October 21, 2022

Upgrades

Via Benzinga

Earnings Outlook For Revolution Medicines ↗

August 08, 2022

Revolution Medicines (NASDAQ:RVMD) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement.

Via Benzinga

$10 Million Bet On This Financial Services Stock? 3 Stocks Insiders Are Buying ↗

July 26, 2022

Although US stocks closed mixed on Monday, there were a few notable insider trades.

Via Benzinga

Earnings Scheduled For August 9, 2022 ↗

August 09, 2022

Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.

Via Benzinga

Revolution Medicines Stock Is Getting Hammered: Here's Why ↗

July 20, 2022

Revolution Medicines Inc (NASDAQ: RVMD) shares are trading lower by 11.25% to $21.82 Wednesday morning after the company announced the pricing of its underwritten public offering of 11,500,000 shares...

Via Benzinga

The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study ↗

July 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.